Phase I clinical investigation of amonafide

R. Saez, J. B. Craig, J. G. Kuhn, G. R. Weiss, J. Koeller, J. Phillips, K. Havlin, G. Harman, J. Hardy, T. J. Melink, G. A. Sarosy, D. D. Von Hoff

    Research output: Contribution to journalArticle

    43 Scopus citations

    Abstract

    Amonafide (benzisoquinolinedione, MSC 308847) is a new synthetic imide antineoplastic agent with DNA intercalative properties that has been evaluated in a phase I clinical trial. The drug was administered as a single intravenous (IV) infusion over 30 to 120 minutes repeated every 28 days. Ninety-five courses of therapy at doses ranging from 18 to 1,104 mg/m2 were administered to 38 patients with refractory solid tumors. Granulocytopenia was dose limiting. Leukopenia was seen in 13 of 31 courses at doses of 690 mg/m2 or greater. Life-threatening granulocytopenia (≤ 250 μL) was noted in 1/6 patients treated at 800 mg/m2, 1/8 patients treated at 918 mg/m2, and 2/5 patients treated at 1,104 mg/m2. No definite relationship between myelotoxicity and prior treatment status was noted. Rate-of-infusion dependent, nonhematologic toxicities included diaphoresis, flushing, dizziness and tinnitus, all of which were ameliorated by increasing the duration of drug infusion to 120 minutes. In addition, nausea and vomiting (grades 1 and 2) were seen in 29/56 courses at doses ≥ 519 mg/m2, but were easily controlled by phenothiazine antiemetics. Amonafide plasma and urine concentrations were determined by high-pressure liquid chromatography (HPLC). Plasma concentrations declined biexponentially with a terminal harmonic mean terminal half-life (t 1/2 ) of 5.5h. The mean apparent volume of distribution at steady-state and total body clearance were 532 L/m2 and 84 L/h/m2, respectively. Less than 5% of the total dose of amonafide was excreted unchanged in the urine. Antitumor activity has been noted in one patient with non-small-cell lung cancer (one complete response exceeding 29 months duration) and in one patient with prostatic cancer (complete pain relief and improvement in bone scan for 9 months). The recommended dose for phase II trials with this schedule of amonafide is 918 mg/m2 with dose escalation to myelotoxicity.

    Original languageEnglish (US)
    Pages (from-to)1351-1358
    Number of pages8
    JournalJournal of Clinical Oncology
    Volume7
    Issue number9
    DOIs
    StatePublished - Jan 1 1989

      Fingerprint

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Saez, R., Craig, J. B., Kuhn, J. G., Weiss, G. R., Koeller, J., Phillips, J., Havlin, K., Harman, G., Hardy, J., Melink, T. J., Sarosy, G. A., & Von Hoff, D. D. (1989). Phase I clinical investigation of amonafide. Journal of Clinical Oncology, 7(9), 1351-1358. https://doi.org/10.1200/JCO.1989.7.9.1351